The TBCRC011 phase II clinical study (35) enrolled 51 AR-positive, ER/PR-negative patients with advanced breast cancer to analyze oral bicalutamide for more than 6 months, and the results showed a clinical benefit rate (CBR) of 19%, a median PFS of 12 weeks, and good tolerability. The gene discussed is ESR1; the disease is breast carcinoma.